Aurobindo Pharma Novartis BASF Viatris *Disclaimer: Top companies sorted in no particular order Saudi Arabia Active Pharmaceutical Ingredients (API) Market Concentration Saudi Arabia Active Pharmaceutical Ingredients (API) Company List Aurobindo Pharma Pfizer Inc. Novartis AG BASF SE...
Key Companies ProfiledSaudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO); Tabuk Pharmaceuticals; Hikma Pharmaceuticals; Julphar Saudi Arabia; Jamjoom Pharma; Modern Pharmaceutical Company (MPC); Ameco Pharmaceutical Company; Tadawi; Al Nahdi Medical Company; Sipco (Saudi Industrial Pr...
Saudi Arabia’s COVID-19 measures helped reduce prevalence of MERS: WHO(Al Arabiya English) Safety measures implemented by Saudi Arabia to reduce the spread of COVID-19 has helped reduce the number of cases of its predecessor Middle East Res...
Who are the key players in Saudi Arabia Active Pharmaceutical Ingredients (API) Market? Pfizer, Inc., Aurobindo Pharma, Novartis AG, BASF SE and Viatris Inc. are the major companies operating in the Saudi Arabia Active Pharmaceutical Ingredients (API) Market. Saudi Arabia Active Ph...
sitcopharma.com Saudi International Trading Company Ltd. (SITCO Pharma)SITCO Pharma was established in 1982. The activity of the subsidiary is concentrated in the distribution of pharmaceutical products in the Kingdom of Saudi Arabia. SITCO Pharma is considered one of the major pharmaceutical distribut...
Saudi Arabia Sodium chloride injectable grade Productname:SodiumchlorideinjectablegradeSynonyms:Commonsalt,Halite,Rocksalt,Saline,Sodiumchloric,TablesaltCASNo.:7647-14-5MolecularFormula:NaCLMolecularWeight:58.44gmol−1Standard:BP,USPSpecificationProducts SodiumChlorideQuality standardIndexStandard ValueNaCl99.0%...
The event will include an exhibition and conference and is being opened to help both regional and international pharma companies partner in one of the world's fastest developing and growing pharma hubs. Saudi Arabia alone is predicted to grow at nearly 10% annually -reaching $19-bn in 2028 -...
CELL AND GENE THERAPIES DEMAND FOR CELL AND GENE THERAPIES IS VOLATILE AND UNPREDICTABLE, BUT DELIVERY MUST BE FAST, ACCURATE AND TIGHTLY CONTROLLED. More than 2,400 new biopharma products are currently undergoing clinical trials END-TO-END CONTROL ...
Powering clinical research for 93%of top pharma companies Real-world data set with more than 108Mpatients Processing more than 10Msafety cases annually Industry recognition via 1.5K+scientific publications in peer reviewed journals and congressesCustomers...
More than80%of top pharma companies use them More than10Mcases processed annually More than70%of drug ICSRs in FDA FAERS More than90%of vaccine ICSRs in FDA VAERS More than90%proven efficiency gains Detect risks, automate processes, increase compliance. ...